• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

MBI warns investors of unsought share bid

Article

Contrast agent developer Molecular Biosystems this month warned its shareholders of an unsought, below-market bid for up to 1% of MBI’s outstanding shares by a company called Towanda Partners ZG. MBI learned of the offer through shareholder queries.

Contrast agent developer Molecular Biosystems this month warned its shareholders of an unsought, below-market bid for up to 1% of MBI’s outstanding shares by a company called Towanda Partners ZG. MBI learned of the offer through shareholder queries. In an Aug. 12 statement, San Diego-based MBI emphasized that it did not endorse the $2.00 per share offer, as stockholders could get a higher price for their shares on the New York Stock Exchange, which on Aug. 11 posted a closing price per share of $2.25. Towanda Partners did not contact MBI before making its offer, which expired on Aug. 16.

Recent Videos
Addressing the Early Impact of National Breast Density Notification for Mammography Reports
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Can 18F-Floutufolastat Bolster Detection of PCa Recurrence in Patients with Low PSA Levels After Radical Prostatectomy?
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Related Content
© 2024 MJH Life Sciences

All rights reserved.